Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

After Menopause, Hormone Therapy Plus Physical Activity Reduce Belly Fat, Body Fat Percentage
Older women who take hormone therapy to relieve menopausal symptoms may get the added benefit of reduced body fat if they are physically active, according to a new study. The results were presented at The Endocrine Society"s 91st Annual Meeting in Washington, D.C.
generic viagra online
New Phase 3 Study Of Tapentadol Immediate Release Tablets Published In Current Medical Research And Opinion Journal
It is estimated that up to 30 percent of all people who have surgery experience gastrointestinal side effects, such as nausea and vomiting. The use of opioid pain medicines during and after surgery is a leading risk factor for experiencing these side effects. Nausea and vomiting are uncomfortable and bothersome and can have an impact on a patient"s recovery.
News of the day
New Poll Finds Disease Prevention Is Top Priority For Americans In Health Reform
Trust for America"s Health (TFAH) and the Robert Wood Johnson Foundation (RWJF) released a new public opinion survey today which finds that Americans rank prevention as the most important health care reform priority, and overwhelmingly support increasing funding for prevention programs to reduce disease and keep people healthy.
Medical Devices

Baxter To Acquire Continuous Renal Replacement Therapy Business From Edwards Lifesciences

Baxter International Inc. (NYSE:BAX) announced today a definitive agreement with Edwards Lifesciences Corporation (NYSE:EW) under which Baxter will acquire certain assets related to Edwards" hemofiltration product line, also known as Continuous Renal Replacement Therapy (CRRT). The transaction is expected to close in the third quarter of 2009, pending regulatory approvals. Under the terms of the agreement, Baxter will provide Edwards an initial cash payment of approximately $56 million upon the close of the transaction. Additionally, Baxter will receive transition services from Edwards and is expected to pay Edwards up to an additional $9 million based on revenue objectives expected to be achieved over the next two years. The impact of this transaction is immaterial to Baxter"s financial results for 2009. Hemofiltration, or CRRT, mimics the function of the kidneys 24 hours a day for patients with life-threatening kidney injuries or edema (fluid overload). CRRT provides a method of continuous yet adjustable fluid removal that can gradually remove excess fluid and waste products that build up with the acute impairment of kidney function, and is usually administered in an intensive care setting in the hospital. Baxter currently supplies solutions used in CRRT treatment globally, and is the exclusive distributor of Edwards" product in China, Latin America and the United States. Approximately 60 employees will be joining Baxter from Edwards as part of this transaction. "As an experienced leader in dialysis therapies including CRRT, this acquisition represents an extension of our existing Renal business, and demonstrates our commitment to save and sustain the lives of patients with acute kidney injuries," said Bruce McGillivray, corporate vice president and president of Baxter"s Renal business. "This acquisition expands Baxter"s existing CRRT business, which is predominantly in the United States and China, into new markets such as Europe and Australia." Baxter International Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009